Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Xalatan (Latanoprost) Reduces Intraocular Eye Pressure Better Than Trusopt (Dorzolamide) PEAPACK, NJ -- October 17, 2000 -- In a study published in the British Journal of Ophthalmology Xalatan® (latanoprost ophthalmic solution) 0.005% once daily provided a significantly greater reduction of intraocular eye pressure (IOP) than Trusopt® (dorzolamide hydrochloride ophthalmic solution) 2.0% three times daily. This study demonstrated that Xalatan is a highly effective medication that lowers IOP in patients with open-angle glaucoma and ocular hypertension. Xalatan is the world’s top-selling glaucoma product and one of Pharmacia Corporation’s top-selling global products, with over 30 million prescriptions written to date. In the United States, Xalatan is indicated for the reduction of elevated IOP in patients with open-angle glaucoma and ocular hypertension who re intolerant of other IOP-lowering medictions or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP lowering medication. "There is significant evidence to show that one drop of Xalatan given on a daily basis will result in the substantial lowering of eye pressure," remarked E.P. O’Donoghue, M.D. of the Department of Ophthalmology at the University College Hospital, Galway, Ireland, and principal investigator of the study. "The convenience of once a day dosing may also increase patient compliance which remains an issue for patients on long term drug therapy." The three month, randomized open-label study performed in the United Kingdom and Ireland involved 224 patients with open-angle glaucoma, capsular glaucoma or ocular hypertension. Effectiveness was judged from the reduction on diurnal IOP and the effect on IOP at peak (maximum effect) and trough (minimum effect). Xalatan reduced mean baseline diurnal IOP of 27.2 mmHg by 8.5 mmHg. The corresponding figures for Trusopt were 27.2 mmHg and 5.6 mmHg. The difference in IOP reduction of 2.9 mmHg, or 52 percent between treatments showed Xalatan to be more effective at lowering diurnal IOP than dorzolamide in this study (p<0.001). The mean IOP reduction for Xalatan-treated patients at peak was 8.6 mmHg (32 percent) compared with 6.2 mmHg (23 percent) for Trusopt-treated patients. The corresponding figures at trough were 8.1 mmHg (31 percent) and 4.7 mmHg (17 percent), respectively. Both drugs were well tolerated systemically and locally. The most common ocular side effect was ocular discomfort. Most adverse events were graded mild or moderate. Glaucoma is a complex group of eye disorders having a common feature of optic nerve damage. It is a leading cause of blindness and vision loss affecting more than eight million people worldwide, up to half of whom are undiagnosed. Conditions commonly associated with glaucoma include elevated intraocular eye pressure, cupping of the optic disc and loss of peripheral vision. There are usually no warning signs with glaucoma. Xalatan contains latanoprost, a prostaglandin analog that is a modification of a naturally occurring substance present in the body. In the eye, prostaglandins appear to reduce IOP by increasing the drainage of aqueous humor. The most frequently reported ocular side effect of patients who were treated with Xalatan include blurred vision, burning and stinging, conjunctival hyperemia, foreign-body sensation, itching, increased iris pigmentation, and punctate epithelial keratopathy. E-mail this page to a friend or colleague! To print, use this version